LEVINE WEIGHS IN ON PARP INHIBITOR ADVANCES IN OVARIAN CANCER
Memorial Sloan Kettering Cancer Center
PRGs
Douglas Levine, MD, director of the Division of Gynecologic Oncology at Perlmutter Cancer Center, NYU Langone School of Medicine, sat down with OncLive at ASCO to provide his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.